Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis. / Greisen, S R; Rasmussen, T K; Stengaard-Pedersen, K; Hetland, M L; Hørslev-Petersen, K; Hvid, M; Deleuran, B.

In: Scandinavian Journal of Rheumatology, Vol. 43, No. 2, 2014, p. 101-108.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Greisen, SR, Rasmussen, TK, Stengaard-Pedersen, K, Hetland, ML, Hørslev-Petersen, K, Hvid, M & Deleuran, B 2014, 'Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis', Scandinavian Journal of Rheumatology, vol. 43, no. 2, pp. 101-108. https://doi.org/10.3109/03009742.2013.823517

APA

Greisen, S. R., Rasmussen, T. K., Stengaard-Pedersen, K., Hetland, M. L., Hørslev-Petersen, K., Hvid, M., & Deleuran, B. (2014). Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis. Scandinavian Journal of Rheumatology, 43(2), 101-108. https://doi.org/10.3109/03009742.2013.823517

Vancouver

Greisen SR, Rasmussen TK, Stengaard-Pedersen K, Hetland ML, Hørslev-Petersen K, Hvid M et al. Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis. Scandinavian Journal of Rheumatology. 2014;43(2):101-108. https://doi.org/10.3109/03009742.2013.823517

Author

Greisen, S R ; Rasmussen, T K ; Stengaard-Pedersen, K ; Hetland, M L ; Hørslev-Petersen, K ; Hvid, M ; Deleuran, B. / Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis. In: Scandinavian Journal of Rheumatology. 2014 ; Vol. 43, No. 2. pp. 101-108.

Bibtex

@article{923c611a205c40a7b5bf963d8a4ef157,
title = "Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis",
abstract = "OBJECTIVES: Programmed death-1 (PD-1) is an immunoregulatory molecule functioning by down-regulating immune responses. PD-1 is present on follicular helper T cells (TFH) and is important in the formation of plasma cells. PD-1 exists in a bioactive soluble form (sPD-1) and is thought to be implicated in disease activity in chronic rheumatoid arthritis (RA).METHOD: We measured sPD-1 at baseline and 9 months after treatment initiation in plasma from early RA patients (n = 34). We tested for correlations with the Disease Activity Score using 28 joint counts (DAS28), the Health Assessment Questionnaire (HAQ) score, immunoglobulin M rheumatoid factor (IgM-RF), anti-cyclic citrullinated peptide (anti-CCP) antibodies, C-reactive protein (CRP), interleukin-21 (IL-21), and total Sharp score (TSS). We also measured sPD-1 in plasma from healthy volunteers (HV) (n = 20) and in plasma and synovial fluid (SF) from patients with chronic RA (> 8 years of disease, n = 30). We further investigated the cellular expression of PD-1 and its ligand PD-L1.RESULTS: sPD-1 concentrations in early [median 0.421 ng/mL, interquartile range (IQR) 0.04-2.560 ng/mL] and chronic (median 0.239 ng/mL, IQR 0.184-0.584 ng/mL) RA were increased compared with HV (median 0.04 ng/mL, IQR 0.04-0.04 ng/mL) (all p < 0.005). In early RA the change in sPD-1 was associated with DAS28 (r = 0.363, p < 0.05) and HAQ score (r = 0.554, p < 0.05) and inversely with TSS at 3-5 years (r = -0.468, p < 0.05). sPD-1 concentration correlated with IgM-RF, anti-CCP antibodies, and IL-21 (all p < 0.05). PD-1 was primarily expressed by synovial memory T cells whereas PD-L1 was mainly expressed by synovial monocytes.CONCLUSIONS: The significantly elevated plasma levels of sPD-1 in early RA, the association with core disease parameters, and the inverse correlation with TSS suggest that sPD-1 is an important mediator in inflammatory and radiographic disease progression.",
keywords = "Aged, Antibodies, Anti-Idiotypic, Arthritis, Rheumatoid, Betamethasone, Biological Markers, Case-Control Studies, Cyclosporine, Disease Progression, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Interleukins, Longitudinal Studies, Male, Methotrexate, Middle Aged, Peptides, Cyclic, Programmed Cell Death 1 Receptor, Rheumatoid Factor, Severity of Illness Index",
author = "Greisen, {S R} and Rasmussen, {T K} and K Stengaard-Pedersen and Hetland, {M L} and K H{\o}rslev-Petersen and M Hvid and B Deleuran",
year = "2014",
doi = "10.3109/03009742.2013.823517",
language = "English",
volume = "43",
pages = "101--108",
journal = "Scandinavian Journal of Rheumatology",
issn = "0300-9742",
publisher = "Taylor & Francis",
number = "2",

}

RIS

TY - JOUR

T1 - Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis

AU - Greisen, S R

AU - Rasmussen, T K

AU - Stengaard-Pedersen, K

AU - Hetland, M L

AU - Hørslev-Petersen, K

AU - Hvid, M

AU - Deleuran, B

PY - 2014

Y1 - 2014

N2 - OBJECTIVES: Programmed death-1 (PD-1) is an immunoregulatory molecule functioning by down-regulating immune responses. PD-1 is present on follicular helper T cells (TFH) and is important in the formation of plasma cells. PD-1 exists in a bioactive soluble form (sPD-1) and is thought to be implicated in disease activity in chronic rheumatoid arthritis (RA).METHOD: We measured sPD-1 at baseline and 9 months after treatment initiation in plasma from early RA patients (n = 34). We tested for correlations with the Disease Activity Score using 28 joint counts (DAS28), the Health Assessment Questionnaire (HAQ) score, immunoglobulin M rheumatoid factor (IgM-RF), anti-cyclic citrullinated peptide (anti-CCP) antibodies, C-reactive protein (CRP), interleukin-21 (IL-21), and total Sharp score (TSS). We also measured sPD-1 in plasma from healthy volunteers (HV) (n = 20) and in plasma and synovial fluid (SF) from patients with chronic RA (> 8 years of disease, n = 30). We further investigated the cellular expression of PD-1 and its ligand PD-L1.RESULTS: sPD-1 concentrations in early [median 0.421 ng/mL, interquartile range (IQR) 0.04-2.560 ng/mL] and chronic (median 0.239 ng/mL, IQR 0.184-0.584 ng/mL) RA were increased compared with HV (median 0.04 ng/mL, IQR 0.04-0.04 ng/mL) (all p < 0.005). In early RA the change in sPD-1 was associated with DAS28 (r = 0.363, p < 0.05) and HAQ score (r = 0.554, p < 0.05) and inversely with TSS at 3-5 years (r = -0.468, p < 0.05). sPD-1 concentration correlated with IgM-RF, anti-CCP antibodies, and IL-21 (all p < 0.05). PD-1 was primarily expressed by synovial memory T cells whereas PD-L1 was mainly expressed by synovial monocytes.CONCLUSIONS: The significantly elevated plasma levels of sPD-1 in early RA, the association with core disease parameters, and the inverse correlation with TSS suggest that sPD-1 is an important mediator in inflammatory and radiographic disease progression.

AB - OBJECTIVES: Programmed death-1 (PD-1) is an immunoregulatory molecule functioning by down-regulating immune responses. PD-1 is present on follicular helper T cells (TFH) and is important in the formation of plasma cells. PD-1 exists in a bioactive soluble form (sPD-1) and is thought to be implicated in disease activity in chronic rheumatoid arthritis (RA).METHOD: We measured sPD-1 at baseline and 9 months after treatment initiation in plasma from early RA patients (n = 34). We tested for correlations with the Disease Activity Score using 28 joint counts (DAS28), the Health Assessment Questionnaire (HAQ) score, immunoglobulin M rheumatoid factor (IgM-RF), anti-cyclic citrullinated peptide (anti-CCP) antibodies, C-reactive protein (CRP), interleukin-21 (IL-21), and total Sharp score (TSS). We also measured sPD-1 in plasma from healthy volunteers (HV) (n = 20) and in plasma and synovial fluid (SF) from patients with chronic RA (> 8 years of disease, n = 30). We further investigated the cellular expression of PD-1 and its ligand PD-L1.RESULTS: sPD-1 concentrations in early [median 0.421 ng/mL, interquartile range (IQR) 0.04-2.560 ng/mL] and chronic (median 0.239 ng/mL, IQR 0.184-0.584 ng/mL) RA were increased compared with HV (median 0.04 ng/mL, IQR 0.04-0.04 ng/mL) (all p < 0.005). In early RA the change in sPD-1 was associated with DAS28 (r = 0.363, p < 0.05) and HAQ score (r = 0.554, p < 0.05) and inversely with TSS at 3-5 years (r = -0.468, p < 0.05). sPD-1 concentration correlated with IgM-RF, anti-CCP antibodies, and IL-21 (all p < 0.05). PD-1 was primarily expressed by synovial memory T cells whereas PD-L1 was mainly expressed by synovial monocytes.CONCLUSIONS: The significantly elevated plasma levels of sPD-1 in early RA, the association with core disease parameters, and the inverse correlation with TSS suggest that sPD-1 is an important mediator in inflammatory and radiographic disease progression.

KW - Aged

KW - Antibodies, Anti-Idiotypic

KW - Arthritis, Rheumatoid

KW - Betamethasone

KW - Biological Markers

KW - Case-Control Studies

KW - Cyclosporine

KW - Disease Progression

KW - Drug Therapy, Combination

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Interleukins

KW - Longitudinal Studies

KW - Male

KW - Methotrexate

KW - Middle Aged

KW - Peptides, Cyclic

KW - Programmed Cell Death 1 Receptor

KW - Rheumatoid Factor

KW - Severity of Illness Index

U2 - 10.3109/03009742.2013.823517

DO - 10.3109/03009742.2013.823517

M3 - Journal article

C2 - 24182347

VL - 43

SP - 101

EP - 108

JO - Scandinavian Journal of Rheumatology

JF - Scandinavian Journal of Rheumatology

SN - 0300-9742

IS - 2

ER -

ID: 138733850